Firebrick Pharma Ltd

NEW
ASX:FRE (Australia)  
A$ 0.091 +0.0010 (+1.11%) Mar 28
At Loss
P/B:
13.00
Market Cap:
A$ 20.42M ($ 12.84M)
Enterprise V:
A$ 19.51M ($ 12.27M)
Volume:
41.99K
Avg Vol (2M):
202.18K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
41.99K
At Loss
Avg Vol (2M):
202.18K

Business Description

Description
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.82
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 31.32
Distress
Grey
Safe
Beneish M-Score 5.86
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Book Growth Rate -45.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 43.01
9-Day RSI 47.34
14-Day RSI 51.89
3-1 Month Momentum % 40.63
6-1 Month Momentum % 50
12-1 Month Momentum % 80

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.44
Quick Ratio 3.63
Cash Ratio 2.68
Days Inventory 1032.87
Days Sales Outstanding 1679
Days Payable 679.52

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5
Shareholder Yield % -7.83

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 105.22
Operating Margin % 257.21
Net Margin % 95.62
FCF Margin % 110.65
ROE % -99.38
ROA % -83.56
ROIC % -546.37
ROC (Joel Greenblatt) % -968.44
ROCE % -108.56

Financials

ASX:FRE's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Firebrick Pharma Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) -1.802
EPS (TTM) (A$) -0.009
Beta 1.38
3-Year Sharpe Ratio -0.01
3-Year Sortino Ratio -0.02
Volatility % 58.6
14-Day RSI 51.89
14-Day ATR (A$) 0.003189
20-Day SMA (A$) 0.09355
12-1 Month Momentum % 80
52-Week Range (A$) 0.045 - 0.11
Shares Outstanding (Mil) 224.39

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Firebrick Pharma Ltd Filings

Filing Date Document Date Form
No Filing Data

Firebrick Pharma Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Firebrick Pharma Ltd Frequently Asked Questions

What is Firebrick Pharma Ltd(ASX:FRE)'s stock price today?
The current price of ASX:FRE is A$0.09. The 52 week high of ASX:FRE is A$0.11 and 52 week low is A$0.05.
When is next earnings date of Firebrick Pharma Ltd(ASX:FRE)?
The next earnings date of Firebrick Pharma Ltd(ASX:FRE) is .
Does Firebrick Pharma Ltd(ASX:FRE) pay dividends? If so, how much?
Firebrick Pharma Ltd(ASX:FRE) does not pay dividend.

Press Release

Subject Date
No Press Release